Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Puration Inc PURA

Puration Inc is engaged in the business of researching, designing, developing, producing, marketing and distributing products and systems to improve the quality of the water used daily by people around the world. The company designs and produces personal use water filter bottles and other containers and also has developed its proprietary technology for water filtration and purification. It derives its revenue from the selling of water filtration products.


GREY:PURA - Post by User

<< Previous
Bullboard Posts
Next >>
Post by Red~Oneon Jul 30, 2020 7:19pm
82 Views
Post# 31347004

Symbols: PAOG, KALY, PURA

Symbols: PAOG, KALY, PURADate: July 30, 2020


PAOG Announces Acquisition Of RespRx Entering $200B Biopharma Market

Symbols: PAOG, KALY, PURA
Sandusky, OH -- July 30, 2020 -- InvestorsHub NewsWire -- PAO Group, Inc. (USOTC: PAOG) today announced the acquisition of RespRx from Kali-Extracts, Inc. (USOTC: KALY). 
 


RespRx is a treatment for Chronic Obstructive Pulmonary Disease (COPD) under development that is derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.” 

The market for COPD treatment is anticipated to reach $14 billion by 2025.

A patent application on the RespRx formulation for symptoms associated with COPD and other similar respiratory conditions has been filedA trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions has also been filed

The global biopharmaceuticals market reached $186,470 million in 2017, and is forecasted to grow to $526,008 million by 2025.

The acquisition announced today is part of PAOG’s overall medical cannabis revitalization strategy. Earlier on Tuesday this week, PAOG announced the acquisition of a cannabis cultivation operation developing a proprietary cannabis cultivar from Puration, Inc. (USOTC: PURA). 

The acquisition of RespRx is an all stock deal.  PAOG has purchased RexpRx from KALY for common stock.  PAOG remains in negotiations with KALY about a potential comprehensive acquisition of the underlying patent from which the RespRx formula was derived.

PAOG CEO James C. DiPrima is scheduled to appear tomorrow, July 31, 2020 on MoneyTV with Donald Baillargeon to discuss the two PAOG acquisitions revitalizing PAOG's long-term medical cannabis mission by launching PAOG into the cannabis biopharmaceutical market.

MoneyTV with Donald Baillargeon is the internationally syndicated television program all about money and what makes it happen, featuring informative interviews with company CEOs and executives, providing insights into their operations and outlooks for their futures. MoneyTV is seen in over 200 million TV households in more than 75 countries.

The MoneyTV Interview will be available Friday July 31st at www.moneytv.net and will be syndicated across multiple channels and platforms. 

<< Previous
Bullboard Posts
Next >>